<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JAMA Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">JAMA Psychiatry</journal-id>
<journal-id journal-id-type="pmc">JAMA Psychiatry</journal-id>
<journal-title-group>
<journal-title>JAMA Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">2168-622X</issn>
<issn pub-type="epub">2168-6238</issn>
<publisher>
<publisher-name>American Medical Association</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29071344</article-id>
<article-id pub-id-type="pmc">6331050</article-id>
<article-id pub-id-type="doi">10.1001/jamapsychiatry.2017.3275</article-id>
<article-id pub-id-type="publisher-id">yoi170078</article-id>
<article-categories>
<subj-group specific-use="electronic" subj-group-type="category">
<subject>Research</subject>
</subj-group>
<subj-group specific-use="print" subj-group-type="domain">
<subject>Research</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Investigation</subject>
</subj-group>
<subj-group subj-group-type="online-first">
<subject>Online First</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression</article-title>
<alt-title alt-title-type="headline">Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression</alt-title>
<alt-title alt-title-type="running-head">Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Hang</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="yoi170078aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Polimanti</surname>
<given-names>Renato</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="yoi170078aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Bao-Zhu</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="yoi170078aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Qian</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="yoi170078aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Shizhong</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="yoi170078aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sherva</surname>
<given-names>Richard</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="yoi170078aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nuñez</surname>
<given-names>Yaira Z.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="yoi170078aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Hongyu</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="yoi170078aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff7">
<sup>7</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff8">
<sup>8</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff9">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Farrer</surname>
<given-names>Lindsay A.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="yoi170078aff6">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff10">
<sup>10</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff11">
<sup>11</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff12">
<sup>12</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff13">
<sup>13</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kranzler</surname>
<given-names>Henry R.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="yoi170078aff14">
<sup>14</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff15">
<sup>15</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gelernter</surname>
<given-names>Joel</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="yoi170078aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff8">
<sup>8</sup>
</xref>
<xref ref-type="aff" rid="yoi170078aff16">
<sup>16</sup>
</xref>
</contrib>
</contrib-group>
<aff id="yoi170078aff1"><label>1</label>Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut</aff>
<aff id="yoi170078aff2"><label>2</label>Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven</aff>
<aff id="yoi170078aff3"><label>3</label>Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut</aff>
<aff id="yoi170078aff4"><label>4</label>Department of Psychiatry, University of Iowa, Iowa City</aff>
<aff id="yoi170078aff5"><label>5</label>Interdisciplinary Graduate Program in Genetics, University of Iowa, Iowa City</aff>
<aff id="yoi170078aff6"><label>6</label>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts</aff>
<aff id="yoi170078aff7"><label>7</label>Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut</aff>
<aff id="yoi170078aff8"><label>8</label>Department of Genetics, Yale University School of Medicine, New Haven, Connecticut</aff>
<aff id="yoi170078aff9"><label>9</label>Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, Connecticut</aff>
<aff id="yoi170078aff10"><label>10</label>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts</aff>
<aff id="yoi170078aff11"><label>11</label>Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts</aff>
<aff id="yoi170078aff12"><label>12</label>Department of Genetics and Genomics, Boston University School of Medicine, Boston, Massachusetts</aff>
<aff id="yoi170078aff13"><label>13</label>Department of Epidemiology and Biostatistics, Boston University School of Public Health, Boston, Massachusetts</aff>
<aff id="yoi170078aff14"><label>14</label>Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia</aff>
<aff id="yoi170078aff15"><label>15</label>Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania</aff>
<aff id="yoi170078aff16"><label>16</label>Department of Neuroscience, Yale University School of Medicine, New Haven, Connecticut</aff>
<author-notes>
<title>Article Information</title>
<corresp id="yoi170078cor1"><bold>Corresponding Author:</bold> Joel Gelernter, MD, Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, 116A2, 950 Campbell Ave, West Haven, CT 06516 (<email xlink:href="joel.gelernter@yale.edu">joel.gelernter@yale.edu</email>).</corresp>
<p><bold>Accepted for Publication:</bold> August 25, 2017.</p>
<p content-type="published-online"><bold>Published Online:</bold> October 25, 2017. doi:<uri content-type="doi">10.1001/jamapsychiatry.2017.3275</uri></p>
<p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Zhou and Gelernter had full access to all the data and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
<p><italic>Study concept and design</italic>: Zhou, Gelernter.</p>
<p><italic>Acquisition, analysis, or interpretation of data</italic>: Zhou, Polimanti, Wang, Sherva, Nuñez, Zhao, Farrer, Kranzler, Gelernter.</p>
<p><italic>Drafting of the manuscript:</italic> Zhou, Gelernter.</p>
<p><italic>Critical revision of the manuscript for important intellectual content:</italic> Zhou, Polimanti, Yang, Han, Sherva, Nuñez, Zhao, Farrer, Kranzler, Gelernter.</p>
<p><italic>Statistical analysis:</italic> Zhou, Polimanti, Yang, Wang, Sherva, Zhao.</p>
<p><italic>Obtained funding:</italic> Kranzler, Gelernter.</p>
<p><italic>Administrative, technical, or material support:</italic> Nuñez, Gelernter.</p>
<p><italic>Study supervision:</italic> Gelernter.</p>
<p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Kranzler reported serving as a consultant or advisory board member for Indivior and Lundbeck and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. No other conflicts were reported.</p>
<p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, and R01 AA017535 from the National Institutes of Health and by the Veterans Affairs Connecticut Healthcare Center and the Philadelphia Veterans Affairs Mental Illness Research, Education and Clinical Center.</p>
<p><bold>Role of the Funder/Sponsor:</bold> The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
<p><bold>Additional Contributions:</bold> James Poling, PhD, Yale University School of Medicine and the APT Foundation; Roger Weiss, MD, McLean Hospital; Kathleen Brady, MD, PhD, and Raymond Anton, MD, Medical University of South Carolina; and David Oslin, MD, the University of Pennsylvania assisted with recruitment and assessment. Genotyping services for a part of our genome-wide association study were provided by the Center for Inherited Disease Research and Yale University (Center for Genome Analysis), which is fully funded by federal contract N01-HG-65403 from the National Institutes of Health to The Johns Hopkins University. Ann Marie Lacobelle, BS, and Christa Robinson, BS, Veterans Affairs Connecticut Healthcare Center, provided technical assistance. Michelle Slivinsky, MA, CCRP, University of Connecticut Health Center, led the Semi-structured Assessment for Drug Dependence and Alcoholism interviews and phenotyping for some of the study sample. John Farrell, PhD, Section of Biomedical Genetics, Boston University School of Medicine, provided database management assistance. All individuals who contributed received support from research grants.</p>
</author-notes>
<pub-date iso-8601-date="2017-10-25T10:00" pub-type="epub">
<day>25</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>25</day>
<month>10</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
<volume>74</volume>
<issue>12</issue>
<fpage>1234</fpage>
<lpage>1241</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="final">
<day>21</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>8</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright 2017 American Medical Association. All Rights Reserved.</copyright-statement>
</permissions>
<self-uri content-type="pdf-version" xlink:href="jamapsychiatry-74-1234.pdf">jamapsychiatry-74-1234.pdf</self-uri>
<self-uri content-type="roundpoint" xlink:href="http://app.jamanetwork.com/?doi=10.1001/jamapsychiatry.2017.3275"></self-uri>
<self-uri content-type="silverchair" xlink:href="http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2017.3275"></self-uri>
<related-article ext-link-type="doi" id="d35e395" related-article-type="commentary" xlink:href="10.1001/jamapsychiatry.2017.3353"></related-article>
<abstract>
<sec id="ab-yoi170078-1">
<title>Importance</title>
<p>Alcohol dependence (AD) and major depression (MD) are leading causes of disability that often co-occur. Genetic epidemiologic data have shown that AD and MD share a common possible genetic cause. The molecular nature of this shared genetic basis is poorly understood.</p>
</sec>
<sec id="ab-yoi170078-2">
<title>Objectives</title>
<p>To detect genetic risk variants for comorbid AD and MD and to determine whether polygenic risk alleles are shared with neuropsychiatric traits or subcortical brain volumes.</p>
</sec>
<sec id="ab-yoi170078-3">
<title>Design, Setting, and Participants</title>
<p>This genome-wide association study analyzed criterion counts of comorbid AD and MD in African American and European American data sets collected as part of the Yale-Penn study of the genetics of drug and alcohol dependence from February 14, 1999, to January 13, 2015. After excluding participants never exposed to alcohol or with missing information for any diagnostic criterion, genome-wide association studies were performed on 2 samples (the Yale-Penn 1 and Yale-Penn 2 samples) totaling 4653 African American participants and 3169 European American participants (analyzed separately). Tests were performed to determine whether polygenic risk scores derived from potentially related traits in European American participants could be used to estimate comorbid AD and MD. </p>
</sec>
<sec id="ab-yoi170078-4">
<title>Main Outcomes and Measures</title>
<p>Comorbid criterion counts (ranging from 0 to 14) for AD (7 criteria) and MD (9 criteria, scaled to 7) as defined by the <italic>DSM-IV</italic>.</p>
</sec>
<sec id="ab-yoi170078-5">
<title>Results</title>
<p>Of the 7822 participants (3342 women and 4480 men; mean [SD] age, 40.1 [10.7] years), the median comorbid criterion count was 6.2 (interquartile range, 2.3-10.9). Under the linear regression model, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/139438618">rs139438618</ext-link> at the semaphorin 3A (<italic>SEMA3A</italic> [OMIM <ext-link ext-link-type="uri" xlink:href="http://omim.org/603961">603961</ext-link>]) locus was significantly associated with AD and MD comorbidity in African American participants in the Yale-Penn 1 sample (β = 0.89; 95% CI, 0.57-1.20; <italic>P</italic> = 2.76 × 10<sup>−8</sup>). In the independent Yale-Penn 2 sample, the association was also significant (β = 0.83; 95% CI, 0.39-1.28; <italic>P</italic> = 2.06 × 10<sup>−4</sup>). Meta-analysis of the 2 samples yielded a more robust association (β = 0.87; 95% CI, 0.61-1.12; <italic>P</italic> = 2.41 × 10<sup>−11</sup>). There was no significant association identified in European American participants. Analyses of polygenic risk scores showed that individuals with a higher risk of neuroticism (β = 1.01; 95% CI, 0.50-1.52) or depressive symptoms (β = 0.87; 95% CI, 0.32-1.42) and a lower level of subjective well-being (β = –0.94; 95% CI, –1.46 to –0.42) and educational attainment (β = –1.00, 95% CI, −1.57 to –0.44) had a higher level of AD and MD comorbidity, while larger intracranial (β = 1.07; 95% CI, 0.50 to 1.64) and smaller putamen volumes (β = –1.16; 95% CI, –1.86 to –0.46) were associated with higher risks of AD and MD comorbidity.</p>
</sec>
<sec id="ab-yoi170078-6">
<title>Conclusions and Relevance</title>
<p><italic>SEMA3A</italic> variation is significantly and replicably associated with comorbid AD and MD in African American participants. Analyses of polygenic risk scores identified pleiotropy with neuropsychiatric traits and brain volumes. Further studies are warranted to understand the biological and genetic mechanisms of this comorbidity, which could facilitate development of medications and other treatments for comorbid AD and MD.</p>
</sec>
</abstract>
<abstract abstract-type="teaser">
<p>This genome-wide association study uses data from the Yale-Penn study to detect genetic risk variants for comorbid alcohol dependence and major depression and to determine whether polygenic risk alleles are shared with neuropsychiatric traits or subcortical brain volumes.</p>
</abstract>
<abstract abstract-type="key-points">
<title>Key Points</title>
<sec id="ab-yoi170078-7">
<title>Question</title>
<p>What specific genetic risk variants are associated with comorbid alcohol dependence and major depression?</p>
</sec>
<sec id="ab-yoi170078-8">
<title>Findings</title>
<p>A replicable genome-wide significant association at <italic>SEMA3A</italic> with comorbid alcohol dependence and major depression was detected in a sample of 4653 African American participants; there was no significant association in a sample of 3169 European American participants.</p>
</sec>
<sec id="ab-yoi170078-9">
<title>Meaning</title>
<p>This study enhances understanding of the genetic mechanisms shared between alcohol dependence and major depression and has implications both for development of medications and for other treatments.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>